Compare AbCellera Biologics Inc (ABCL) vs Flux Power Holdings Inc (FLUX) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FLUX trades at $0.8199, down 8.75% over 24 hours. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $6.67 million in 2025 with a negative net margin of 12.48%, while revenue declined to $51 million in 2026. Recent developments include the launch of SkyEMS 3.0 AI software and new executive appointments aimed at growth.

Outlook remains speculative with unanimous analyst buy ratings contrasting weak profitability. Key opportunities lie in software innovation and market expansion, but risks include persistent losses, revenue volatility, and intense clean energy competition. The stock's appeal hinges on execution turning losses to profits.